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Summary Using flow cytometry and immunocytochemistry, we investigated the reactivities of two different
murine monoclonal antibodies (MAbs), MRK 16 and MRK 20, specific to adriamycin-resistant K562 cells
(K562/ADM) with peripheral human mononuclear cells (MNC) (mainly blastic cells and lymphocytes) from 31
patients with leukaemia or malignant lymphoma. Reactivity with MRK 16 MAb was observed in five cases
and reactivity with MRK 20 MAb in 18 cases. The cases were divided into three groups according to their
reactivity patterns: group I, only the proportion of MRK 16-positive cells was increased; group 11, only the
proportion of MRK 20-positive cells was increased; group III, both MRK 16- and MRK 20-positive cells were
increased. Some cases reflected the prior administration of adriamycin, vincristine, vinblastine and VP-16,
which are known to induce P-glycoprotein expression. Expression of M, 85,000 protein was observed more
frequently than that of P-glycoprotein in leukaemia and malignant lymphoma, and this was not associated
with either the total dose or period of administration of anticancer drugs. The expression of Mr 85,000
protein recognised by MRK 20 was further confirmed by Western blot analysis.
The appearance of multidrug resistance during treatment of
various malignancies with anticancer agents must be detected
as soon as possible. In an attempt to achieve this, we first
established an adriamycin-resistant cell line, K562 (K562/
ADM), from its parental line, K562 (Tsuruo et al., 1986),
and finally obtained several murine monoclonal antibodies
(MAbs) reactive with K562/ADM by immunising mice with
these cells and hybridising the spleen cells from these animals
with murine myeloma cells (Hamada & Tsuruo, 1986;
Hamada et al., 1989). Of these MAbs, MRK 16 recognised
Mr 170,000-180,000 P-glycoprotein, while another, MRK 20,
recognised an Mr 85,000 protein (Hamada & Tsuruo, 1986;
Hamada et al., 1989). Both proteins seem to be associated
with the mechanism of multidrug resistance (Pastan & Got-
tesman, 1987; Sugawara et al., 1988b).
In the present study, we utilised these two MAbs, MRK 16
and MRK 20, to investigate their potential usefulness for the
detection of multidrug-resistant cancer cells during treatment
of leukaemia and malignant lymphoma.
Materials and methods
Patients
The subjects of this study were 31 patients referred to the
Department of Internal Medicine, Institute of Medical
Science, University of Tokyo, for evaluation and therapy of
haematological malignancies.
Flow cytometry
Whole peripheral blood was reacted with MRK 16
(5 ytg ml-'), MRK 20 (5jig ml-') or non-immune mouse
serum (Sigma, 5 jg ml-') at 4°C for 20 min. After two
washings with PBS, the cells were reacted with FITC-labelled
goat anti-mouse IgGs (F(ab')2 fragments) (1:40 diluted,
Tago, USA) at 4°C for 30 min. After two further washings,
erythrocytes in the whole peripheral blood were haemolysed
with a lysing agent (Coulter, USA). Peripheral mononuclear
cells (MNC) thus obtained were examined for MRK 16 or
MRK 20 positivity using a Spectrum III flow cytometer
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(Ortho Diagnostics Systems Inc., Raritan, NJ). The degree of
positivity with MRK 16 or MRK 20 MAb was expressed as
the percentage of MRK 16- or MRK 20-positive cells relative
to the percentage of positive cells following treatment with
non-immune mouse IgGs used as a negative control.
Immunocytochemistry
At the same time, blood samples from the 31 patients were
saved for further immunohistochemical examination.
Peripheral mononuclear cells (MNC) were obtained by cent-
rifugation on a Ficoll-Hypaque cushion at 2,000 r.p.m. for
25 min (Sugawara et al., 1986). The MNC consisted mainly
of lymphocytes and monocytes as assessed by the
immunofluorescence antibody technique. For
immunocytochemistry, the ABC-PO method was utilised
(Hsu et al., 1981; Sugawara et al., 1988b).
Western blotting
In order to clarify whether MRK 20-positive cells really
possessed the Mr 85,000 protein specifically expressed by
adriamycin-resistant K562 cells, Western blotting was per-
formed. Peripheral MNC from cases NA and KY
(5 x 106 ml -') were solubilised according to Laemmli's
method (Laemmli, 1970). Briefly, the cells were solubilised
with 500jil of cell lysis buffer containing 1% Triton Xl00,
1% sodium deoxycholate, 0.1% sodium dodecyl sulphate
(SDS), 0.15 M NaCI, 50 mM Tris-HCI (pH 7.4) and 2 mM
phenylmethylsulphonyl fluoride (PMSF). After the solubilised
proteins had been subjected to SDS-PAGE, they were trans-
ferred on to nitrocellulose membrane filters. Thereafter,
immunochemistry (ABC-PO method) was carried out for
detection of the protein (Hsu et al., 1981).
Results
Flow cytometric and immunocytometric ftatures
Table I shows the clinical diagnosis, anti-cancer drugs used
and MRK 16 and MRK 20 reactivities of peripheral
mononuclear cells (MNC) from the patients with leukaemia
and malignant lymphoma before or during treatment. MRK
16 and MRK 20 reactivities of peripheral lymphocytes from
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Table I Clinical profile of patients used in this study and reactivities of their peripheral blastic cells with MRK 16 and MRK 20 MAbs
Reactivityc
with
Patient Clinical diagnosiP Anticancer drugs usedX MRK 16 MRK20(%)
NH CML (blastic crisis) BHAC (12250 mg), ACM (1225), 6MP (4620), PSL 0.8 19.3
(1920), DNR (790), Ara-C (63.6 g), VCR (4)
NA CML (blastic crisis) busulfan, HU, IFN-a (21300 IU), Ara-C (2310), NHAC 4.5 17.3
(1750), PL-AC (5100), VDS (23), DNR (160), ACM
(140), MTX (60), 6MP (3400), PSL (330), mithramycin
(6250), ifosphamide (5 g)
IS APL BHAC (4400), DNR (200), 6MP (10.55 g), PSL (2500), 12.8 17.6
ADR (240), Ara-C (440)
TS AMM L BHAC (5300), 6MP (700), PSL (210), DNR (80), Ara-C 1.7 18.3
(3150), VP-16 (2250), VCR (3.6), VB (27)
FR AML BHAC (1000), 6MP (100), DNR (80) 0.5 2.2
IH CLL none 0.1 3.4
KY Malignant lymphoma cisplatin, CVR, PSL, L-asp, CY, peplomycin, ADR 0.1 9.1
TT Burkitt lymphoma CY (800), ADR (50), VCR (2), PSL (500) 0.1 0.7
ET ALL none 0.0 0.0
IK ALL none 0.0 7.7
SM ALL none 0.2 0.7
OE ALL CY (10860), VCR (19.6), PSL (6170), procarbazine 1.8 4.1
(7400), ADR (423), VBL (72), BM (120), dacarbazine
(4000), VP-16 (700), Nitromin (200)
FH APL BHAC (3500), DNR (490), 6MP (700), PSL (210) 0.0 12.7
NR CML IFN-a (> 12 x 106 U) 0.0 18.4
SK APL none 1.0 0.0
SY AML BHAC, DNR, 6MP, PSL 0.0 0.4
HH NHL PSL (900), CY (2400), VCR (4), ADR (140) 0.0 2.5
TK AML BHAC (2500), 6MP (1000), DNR (120), PSL (1095) 4.7 2.0
FH APL BHAC (3500), DNR (490), 6MP (700), PSL (210) 0.0 12.7
NN AML BHAC, DNR, 6MP, PSL, Ara-C, ADR 0.0 1.7
HA CML INF-x(426 x 106 U) 2.9 21.6
KF CML IFN-a (12 x 106U) 0.0 0.0
KS CML 6MP, HU (24500) 0.0 2.4
KK CML IFN-a (1000 x 106U) 0.1 1.8
TK CML none 0.0 1.2
TM CML IFN-a (6 x 106 U) 0.0 5.6
KS CML IFN-a (6 x 106U) 0.0 5.7
KN CML IFN-a (20 x 106 U) 0.0 5.2
HK CML IFN-a (237 x 106 U), Busulfan (2), HU (1500) 0.0 0.9
TT AML AraC (5070), BHAC (15500), 6MP (1160), DNR (1060) 0.0 0.0
FR AML PSL (900), BHAC (19750), 6MP (3600), DNR (520), 0.0 15.8
VP16 (800), VCR (1.5), Ara-C (38400), VBL (10),
Mitxantrone (57.6)
dCML, chronic myelogenous leukaemia; APL, acute promyelocytic leukaemia; AMMoL acute myelomonocytic leukaemia; AML, acute
myelogenous leukaemia, CLL, chronic lymphocytic leukaemia; ALL, acute lymphocytic leukaemia; NHL, non-Hodgkin's lymphoma. bBHAC,
behenoylcytosine arabinoside; ACM, aclacinomycin; PSL, prednisolone; 6MP, 6-mercaptopurine; Ara-C, cytosine arabinoside; DNR,daunomycin;
VCR, vincristine; MTX, methotrexate; PL-AC-N4, palmitoyl-(1'-P'-D-arabinofuranosyl) cytosine; VP-16, etoposide; VB, vinblastine; L-asp,
L-asparaginase; CY, cyclophosphamide; BM, bleomycin; HU, hydroxyurea; VDS, vindesine; IFN-a, interferon-a. Numbers in parentheses indicate
total doses in mg. Drug abbreviation only indicates unknown dose. CReactivities oflymphocytes from normal healthy volunteers with MRK 16 and
MRK 20 MAbs were 0 1% and 0-2%, respectively.
10 normal healthy volunteers were 0.0-1.0% and 0.0-2.0%,
respectively. MRK 16 and MRK 20 reactivities of areas
containing blastic cells and lymphocytes were determined
using a Spectrum III. Of the 31 cases, an increase in the
proportion of MRK 16-positive cells was found in five cases,
while an increase in MRK 20-positive cells was observed in
18. The reactivity patterns of MRK 16 and MRK 20 in the
31 cases were divided into three groups: group I, increase in
the proportion of MRK 16-positive cells; group II, increase
in the proportion of MRK 20-positive cells; group III, inc-
rease of both MRK 16- and MRK 20-positive cells
(Figure 1). An increase of MRK 16-positive cells reflected the
administration of anticancer drugs, while an increase of
MRK 20-positive cells was unrelated to either the dose of
anti-cancer drugs used or the period of their administration.
Figures 2 and 3 each show a typical picture of MRK 16- or
MRK 20-positive blasts (case NA and KY) as evaluated by
immunocytochemistry (ABC-PO method). MRK 16- and
MRK 20-positive cells were considered to be blastic cells on
the basis of morphological criteria.
Western blot analysis
To examine whether MRK 20-positive cells really expressed
the corresponding M, 85,000 protein, Western blotting was
carried out. As shown in Figure 4, an M, 85,000 band was
detected by the MRK 20 MAb.
Discussion
Our present data revealed several interesting features. First,
P-glycoprotein was detected in haematological malignancies.
Tsuruo et al. (1987) and Ma et al. (1987) have also reported
similar findings. It was clearly apparent that expression of
P-glycoprotein wasclosely related to the prior administration of
anticancer drugs. Although we determined the total amounts of
anticancer drugs used, we were unable to detect exactly when
during the treatment P-glycoprotein appeared in the cells. On
the other hand, the M, 85,000 protein recognised by MRK 20
MAb was detected both before and during treatment of
haematological malignancies. It has been reported recently that
an Mr 85,000 protein is closely associated with resistance to
adriamycin (Hamada et al., 1989; Sugawara et al., 1988b). We
had also been able to confirm the appearance ofthe M, 85,000
protein during treatment of K 562 cells with adriamycin (our
unpublished data). Thecomplete amino acid sequence oftheMr
85,000 protein is still unknown, but it appears to be of some
importance in view of its high frequency of detection (ap-
prox. 60%).540 I. SUGAWARA et al.
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Figure 1 Flow cytometric profiles of case TK (a) and case HA
(b). a: top, MRK 16-positive cells (4.7%); middle, MRK 20-
positive cells (2.0%); bottom, non-immune serum as negative
control (0.5%). A horizontal line ( ) shows a negative gated
area consisting of MRK 16-negative or MRK 20-negative cells. b:
tops, MRK 16-positive cells (2.9%); middle, MRK 20-positive
cells (21.6%); bottom, non-immune serum as negative control
(0.1%). A horizontal line ( ) shows a negative gated area
consisting of MRK 16-negative or MRK 20-negative cells.
Figure 3 Reactivity of blastic cells (case KY) with MRK 20
MAb. ABC-PO method. x 570. Blastic cells are stained positively
(arrow).
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Figure 2 Reactivity of blastic cells (case NA) with MRK 16
MAb. ABC-PO method. x 570. Some blastic cells are stained
positively (arrow).
The second important point is that some haematological
malignancies appear to show intrinsic drug resistance, as
indicated in Table I. It has already been suggested that intrinsic
drug resistance mechanisms exist in some solid tumours such as
kidney, lung and breast cancer (Fojo et al., 1987; Sugawara et
al., 1988a). Expression ofMr85,000protein appears to be much
more closely associated with intrinsic drug resistance in
haematological malignancies. As we were unable to examine
whether MRK 16- and MRK 20-positive cells are resistant to
certain anticancer drugs due to paucity of the cells, this aspect
awaits further study. However, both MRK 16- and MRK 20-
Figure 4 Western blot analysis of solubilised proteins from
K562, K562/ADM (K/A), case KY, and case NA. Approximately
50 ptg of the solubilised protein was subjected to SDS-PAGE
under reducing conditions before blotting. Thereafter, the pro-
teins were reacted with MRK 20 MAb (IOgLgml-'). A major
band of approx. M, 85,000 is visible in each of the K/A, NA and
KY lanes.
negative leukaemic cells were sensitive to adriamycin and
vincristine in terms ofIC50, in comparison with K 562 cells (our
unpublished data).
Finally, from our present data, it is suggested that MRK 16
and MRK 20 MAbs may have two potentially useful clinical
applications. One is that the MAbs, either by themselves or in
combination with toxins or radioisotopes, could be used for
selective ex vivo killing of cancer cells containing high levels of
P-glycoprotein. The other is that the MAbs could be useful for
detecting the degree ofmultidrug resistance in various types of
malignancy in vitro.
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